中华风湿病学杂志
中華風濕病學雜誌
중화풍습병학잡지
CHINESE JOURNAL OF RHEUMATOLOGY
2011年
9期
634-637
,共4页
赵欣欣%毕莹%贾秀坤%闵睿%尹晓燕
趙訢訢%畢瑩%賈秀坤%閔睿%尹曉燕
조흔흔%필형%가수곤%민예%윤효연
关节炎,实验性%免疫耐受%胶原Ⅱ型%霍乱毒素%小鼠
關節炎,實驗性%免疫耐受%膠原Ⅱ型%霍亂毒素%小鼠
관절염,실험성%면역내수%효원Ⅱ형%곽란독소%소서
Arthritis,experimental%Immune tolerance%Collagen typeⅡ%Cholera toxin%Mice
目的 关节炎急性期胶原诱导性关节炎(CIA)小鼠口服Ⅱ型胶原免疫活性肽段(250-270))[CⅡ(250-270)]和霍乱毒素B亚单位(CTB)的共价复合物,观察其是否能产生免疫耐受。方法 DBA/1小鼠分成Ⅰ、Ⅱ、Ⅲ、Ⅳ组,Ⅰ组为健康对照,Ⅱ、Ⅲ、Ⅳ组小鼠制成CIA。Ⅲ组小鼠于关节炎发病率达到100%后,灌胃CⅡ(250-270 )-CTB共价复合物,Ⅳ组小鼠于初次免疫后第14日灌胃CⅡ(250-270)与CTB的混合物。记录小鼠关节炎症评分及病理评分。关节炎发生率比较采用Fisher精确概率法,关节炎累计评分及组织病理累计评分采用方差分析。结果 Ⅰ、Ⅱ、Ⅲ、Ⅳ组的关节炎发生率分别为0、100%、100%和25%;关节炎累计评分均值分别为0、5.0±1.7、10.8±2.8和1.0±2.0;关节炎病理累计评分均值分别为0、16±8、32±13和7±6。结论 CIA小鼠于免疫后的关节炎临床前期口服CⅡ( 250-270)与CTB的混合物能抑制关节炎的发生及严重程度,关节炎急性炎症期口服CⅡ(250-270)-CTB共价复合物后可能使关节炎症加重。
目的 關節炎急性期膠原誘導性關節炎(CIA)小鼠口服Ⅱ型膠原免疫活性肽段(250-270))[CⅡ(250-270)]和霍亂毒素B亞單位(CTB)的共價複閤物,觀察其是否能產生免疫耐受。方法 DBA/1小鼠分成Ⅰ、Ⅱ、Ⅲ、Ⅳ組,Ⅰ組為健康對照,Ⅱ、Ⅲ、Ⅳ組小鼠製成CIA。Ⅲ組小鼠于關節炎髮病率達到100%後,灌胃CⅡ(250-270 )-CTB共價複閤物,Ⅳ組小鼠于初次免疫後第14日灌胃CⅡ(250-270)與CTB的混閤物。記錄小鼠關節炎癥評分及病理評分。關節炎髮生率比較採用Fisher精確概率法,關節炎纍計評分及組織病理纍計評分採用方差分析。結果 Ⅰ、Ⅱ、Ⅲ、Ⅳ組的關節炎髮生率分彆為0、100%、100%和25%;關節炎纍計評分均值分彆為0、5.0±1.7、10.8±2.8和1.0±2.0;關節炎病理纍計評分均值分彆為0、16±8、32±13和7±6。結論 CIA小鼠于免疫後的關節炎臨床前期口服CⅡ( 250-270)與CTB的混閤物能抑製關節炎的髮生及嚴重程度,關節炎急性炎癥期口服CⅡ(250-270)-CTB共價複閤物後可能使關節炎癥加重。
목적 관절염급성기효원유도성관절염(CIA)소서구복Ⅱ형효원면역활성태단(250-270))[CⅡ(250-270)]화곽란독소B아단위(CTB)적공개복합물,관찰기시부능산생면역내수。방법 DBA/1소서분성Ⅰ、Ⅱ、Ⅲ、Ⅳ조,Ⅰ조위건강대조,Ⅱ、Ⅲ、Ⅳ조소서제성CIA。Ⅲ조소서우관절염발병솔체도100%후,관위CⅡ(250-270 )-CTB공개복합물,Ⅳ조소서우초차면역후제14일관위CⅡ(250-270)여CTB적혼합물。기록소서관절염증평분급병리평분。관절염발생솔비교채용Fisher정학개솔법,관절염루계평분급조직병리루계평분채용방차분석。결과 Ⅰ、Ⅱ、Ⅲ、Ⅳ조적관절염발생솔분별위0、100%、100%화25%;관절염루계평분균치분별위0、5.0±1.7、10.8±2.8화1.0±2.0;관절염병리루계평분균치분별위0、16±8、32±13화7±6。결론 CIA소서우면역후적관절염림상전기구복CⅡ( 250-270)여CTB적혼합물능억제관절염적발생급엄중정도,관절염급성염증기구복CⅡ(250-270)-CTB공개복합물후가능사관절염증가중。
Objective The aim of this study is to investigate whether oral administration of collagen Ⅱ peptide (250-270)[C Ⅱ (250-270)]-cholera toxin B subunit (CTB) complex could effectively set up oral immune tolerance to collagen-induced arthritis (CIA) in mice. Methods DBA/1 mice were divided into Ⅰ, Ⅱ, Ⅲ and Ⅳgroups. Group Ⅰ was normal control group. Collagen type Ⅱ emulsified in Freund's complete adjuvant were injected to mice of groups Ⅱ , Ⅲ and Ⅳ twice from the base of the tail. Mice of group Ⅲ were fed with C Ⅱ (250-270)-CTB covalent complex twice after the arthritis was developed. Mice of group Ⅳ were fed with C Ⅱ (250-270) and CTB mix at the 14th day after primary immunization. Visual scores and histopathologic scores of arthritis were recorded. The frequencies of arthritis between the groups were compared using Fisher's exact test. The clinical and histological severity of arthritis were analyzed by ANOVA.Results The frequencies of arthritis in groups Ⅰ , Ⅱ , Ⅲ and Ⅳ were 0, 100%, 100% and 25% respectively. Average accumulative scores of arthritis were 0, 5.0±1.7, 10.8±2.8 and 1.0±2.0 respectively. Average accum-ulative histopathological scores of arthritis were 0, 16±8, 32±13 and 7±6 respectively. Conclusion Oral administration of C Ⅱ (250-270) and CTB mix in arthritis mice after C Ⅱ immunization can suppress the onset and severity of arthritis. Oral administration of C Ⅱ (250-270)-CTB covalent complex in the acute stage of arthritis can accelerate arthritis.